These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 18091526

  • 1. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C.
    Transplantation; 2007 Dec 15; 84(11):1492-9. PubMed ID: 18091526
    [Abstract] [Full Text] [Related]

  • 2. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
    Keller K, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C.
    Nephrol Dial Transplant; 2006 Oct 15; 21(10):2724-35. PubMed ID: 16861242
    [Abstract] [Full Text] [Related]

  • 3. Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction.
    Rovira J, Arellano EM, Carreras J, Campos B, Vodenik B, Bañón-Maneus E, Ramírez-Bajo MJ, Moya-Rull D, Solé-González A, Hernández A, Revuelta I, Quintana LF, Howat WJ, Campistol JM, Diekmann F.
    Transplantation; 2009 Sep 15; 88(5):646-52. PubMed ID: 19741461
    [Abstract] [Full Text] [Related]

  • 4. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
    Diekmann F, Rovira J, Carreras J, Arellano EM, Bañón-Maneus E, Ramírez-Bajo MJ, Gutiérrez-Dalmau A, Brunet M, Campistol JM.
    J Am Soc Nephrol; 2007 Oct 15; 18(10):2653-60. PubMed ID: 17804674
    [Abstract] [Full Text] [Related]

  • 5. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
    Krämer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2008 Feb 15; 294(2):F440-9. PubMed ID: 18094032
    [Abstract] [Full Text] [Related]

  • 6. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL.
    Am J Physiol Renal Physiol; 2009 Dec 15; 297(6):F1597-605. PubMed ID: 19776171
    [Abstract] [Full Text] [Related]

  • 7. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats.
    Nakagawa S, Masuda S, Nishihara K, Inui K.
    Biochem Pharmacol; 2010 Jan 01; 79(1):67-76. PubMed ID: 19660439
    [Abstract] [Full Text] [Related]

  • 8. Parenchymal injury in remnant-kidney model may be linked to apoptosis of renal cells mediated by nitric oxide.
    Hruby Z, Rosinski M, Tyran B.
    J Nephrol; 2008 Jan 01; 21(5):686-93. PubMed ID: 18949723
    [Abstract] [Full Text] [Related]

  • 9. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
    Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W.
    J Am Soc Nephrol; 2005 Jul 01; 16(7):2063-72. PubMed ID: 15917339
    [Abstract] [Full Text] [Related]

  • 10. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
    Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL.
    Kidney Blood Press Res; 2007 Jul 01; 30(4):253-9. PubMed ID: 17596700
    [Abstract] [Full Text] [Related]

  • 11. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, Herrero-Fresneda I, Franquesa Ml, Rama I, Grinyó JM.
    Nephrol Dial Transplant; 2008 Oct 01; 23(10):3111-9. PubMed ID: 18469305
    [Abstract] [Full Text] [Related]

  • 12. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
    Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyó JM.
    J Am Soc Nephrol; 2006 May 01; 17(5):1395-404. PubMed ID: 16597691
    [Abstract] [Full Text] [Related]

  • 13. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 14. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat.
    Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, Kawachi H, Hugo C.
    Nephron Exp Nephrol; 2008 Mar 01; 108(2):e45-56. PubMed ID: 18270495
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT, Yin JL, Wyburn K, Wu H, Eris JM, Hambly BD, Chadban SJ.
    Nephrol Dial Transplant; 2013 Feb 01; 28(2):327-36. PubMed ID: 23229928
    [Abstract] [Full Text] [Related]

  • 16. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients.
    Koch M, Mengel M, Poehnert D, Nashan B.
    Transplantation; 2007 Feb 27; 83(4):498-505. PubMed ID: 17318083
    [Abstract] [Full Text] [Related]

  • 17. The mesangium in the long-term remnant kidney model.
    Schwartz MM, Evans J, Bidani AK.
    J Lab Clin Med; 1994 Nov 27; 124(5):644-51. PubMed ID: 7964122
    [Abstract] [Full Text] [Related]

  • 18. Influence of dietary protein/calorie intake on renal morphology and function in cats with 5/6 nephrectomy.
    Adams LG, Polzin DJ, Osborne CA, O'Brien TD, Hostetter TH.
    Lab Invest; 1994 Mar 27; 70(3):347-57. PubMed ID: 8145529
    [Abstract] [Full Text] [Related]

  • 19. A re-evaluation of the renal ablation model of progressive renal disease in rats.
    Kim KH, Kim Y, Park HW, Jeong HJ, Mauer M.
    J Nephrol; 2003 Mar 27; 16(2):196-202. PubMed ID: 12768066
    [Abstract] [Full Text] [Related]

  • 20. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
    Letavernier E, Legendre C.
    Transplant Rev (Orlando); 2008 Apr 27; 22(2):125-30. PubMed ID: 18631865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.